Organogenesis Holdings Inc. logo ORGO - Organogenesis Holdings Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 4
HOLD 1
SELL 0
STRONG
SELL
0
| PRICE TARGET: $3.00 DETAILS
HIGH: $3.00
LOW: $3.00
MEDIAN: $3.00
CONSENSUS: $3.00
UPSIDE: 21.46%

About Organogenesis Holdings Inc. (https://organogenesis.com)

Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.

Key Executives

NAME TITLE DOB SALARY
Gary S. Gillheeney President, Chief Executive Officer, Chair of the Board 1955 $2,598,407 USD
Lori H. Freedman Chief Administrative & Legal Officer 1967 $1,075,162 USD
Brian Grow Chief Commercial Officer 1976 $1,050,859 USD
Patrick Bilbo Chief Operating Officer 1962 $1,017,946 USD
David C. Francisco Chief Financial Officer 1966 $1,000,875 USD
Patrick McGuire Chief Accounting Officer 1986
Robert Cavorsi Chief Business Officer 1979
William R. Kolb Secretary

Company Peers

Peer analysis pending, check back in 1-2 minutes.